The global companion diagnostics market size is expected to reach USD 15.98 billion by 2030, registering a CAGR of 10.5% from 2025 to 2030. Companion diagnostics are specialized tests designed to ensure the safe and effective use of specific therapeutic products by identifying corresponding biomarkers in patients. These tests are predominantly employed in oncology, where they guide clinicians in selecting the most appropriate targeted therapies based on a patient’s unique genetic profile. For instance, Foundation Medicine’s FOUNDATIONONE CDx analyzes over 300 cancer-related genes, providing critical insights that inform precision cancer treatments across various solid tumors. By identifying key mutations or genetic alterations, companion diagnostics facilitate personalized treatment regimens, thereby improving clinical outcomes and reducing the risk of adverse reactions. This individualized approach to therapy not only enhances patient care but also supports the broader shift towards precision medicine, where treatment strategies are tailored to the genetic makeup of each patient.
Regulatory approvals play a pivotal role in bolstering the companion diagnostics market, particularly in oncology. In August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.’s Oncomine Dx Target Test, a companion diagnostic designed to identify HER2 (ERBB2) activating mutations-including single nucleotide variants and exon 20 insertions - in non-small cell lung cancer tumors. Such regulatory endorsements validate the clinical utility of these tests and promote their widespread adoption. Additionally, the use of advanced techniques such as Next-Generation Sequencing (NGS) has become integral to companion diagnostics. NGS enables clinicians to evaluate multiple genes simultaneously, thereby providing comprehensive tumor profiling. The Centers for Disease Control and Prevention (CDC) has highlighted that NGS has successfully transitioned from a research tool to a clinically approved method within the past five years, underscoring its growing importance in diagnostic applications.
Technological innovation is a critical driver of growth in the companion diagnostics market. Key industry players are continuously advancing NGS platforms, digital ELISA, and liquid biopsy techniques to improve diagnostic precision and efficiency. Strategic partnerships are further accelerating these developments; for instance, in November 2023, QIAGEN partnered with Element Biosciences to provide NGS workflows for the benchtop sequencer AVITI System, aiming to enhance discovery, reduce costs, and improve turnaround times in genomic research. Similarly, in January 2022, Illumina Inc. collaborated with SomaLogic Operating Co., Inc. to integrate the SomaScan proteomics assay into its high-throughput NGS platforms. These collaborations not only expand the technological capabilities of companion diagnostics but also foster innovation in the development of new testing solutions, ensuring that emerging diagnostic methods keep pace with evolving clinical needs.
The rising prevalence of cancer globally has significantly spurred the adoption of companion diagnostics, as genomic testing offers a detailed insight into tumor biology that is critical for selecting effective treatment protocols. According to data from the American Cancer Society Journal, approximately 1.9 million new cancer cases were reported in the U.S. in 2022, while the World Health Organization (WHO) noted that in the same year, there were 2.26 million new breast cancer cases and 2.21 million new lung cancer cases worldwide. In response to these challenges, novel tests are being developed to detect specific genetic mutations. For example, in August 2020, the U.S. FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that employs NGS technology to detect EGFR gene mutations in metastatic non-small cell lung cancer. In October 2023, QIAGEN further strengthened its market position by partnering with Myriad Genetics to develop advanced companion diagnostic solutions for oncology, thereby enhancing personalized treatment strategies and improving patient outcomes.
This product will be delivered within 1-3 business days.
Regulatory approvals play a pivotal role in bolstering the companion diagnostics market, particularly in oncology. In August 2022, the U.S. FDA approved Thermo Fisher Scientific Inc.’s Oncomine Dx Target Test, a companion diagnostic designed to identify HER2 (ERBB2) activating mutations-including single nucleotide variants and exon 20 insertions - in non-small cell lung cancer tumors. Such regulatory endorsements validate the clinical utility of these tests and promote their widespread adoption. Additionally, the use of advanced techniques such as Next-Generation Sequencing (NGS) has become integral to companion diagnostics. NGS enables clinicians to evaluate multiple genes simultaneously, thereby providing comprehensive tumor profiling. The Centers for Disease Control and Prevention (CDC) has highlighted that NGS has successfully transitioned from a research tool to a clinically approved method within the past five years, underscoring its growing importance in diagnostic applications.
Technological innovation is a critical driver of growth in the companion diagnostics market. Key industry players are continuously advancing NGS platforms, digital ELISA, and liquid biopsy techniques to improve diagnostic precision and efficiency. Strategic partnerships are further accelerating these developments; for instance, in November 2023, QIAGEN partnered with Element Biosciences to provide NGS workflows for the benchtop sequencer AVITI System, aiming to enhance discovery, reduce costs, and improve turnaround times in genomic research. Similarly, in January 2022, Illumina Inc. collaborated with SomaLogic Operating Co., Inc. to integrate the SomaScan proteomics assay into its high-throughput NGS platforms. These collaborations not only expand the technological capabilities of companion diagnostics but also foster innovation in the development of new testing solutions, ensuring that emerging diagnostic methods keep pace with evolving clinical needs.
The rising prevalence of cancer globally has significantly spurred the adoption of companion diagnostics, as genomic testing offers a detailed insight into tumor biology that is critical for selecting effective treatment protocols. According to data from the American Cancer Society Journal, approximately 1.9 million new cancer cases were reported in the U.S. in 2022, while the World Health Organization (WHO) noted that in the same year, there were 2.26 million new breast cancer cases and 2.21 million new lung cancer cases worldwide. In response to these challenges, novel tests are being developed to detect specific genetic mutations. For example, in August 2020, the U.S. FDA approved Guardant360 CDx, the first liquid biopsy companion diagnostic that employs NGS technology to detect EGFR gene mutations in metastatic non-small cell lung cancer. In October 2023, QIAGEN further strengthened its market position by partnering with Myriad Genetics to develop advanced companion diagnostic solutions for oncology, thereby enhancing personalized treatment strategies and improving patient outcomes.
Companion Diagnostics Market Report Highlights
- Based on product and services segment, assays, kits, and reagents led the market with a 59.1% share in 2024, driven by increasing demand for personalized medicine and targeted therapies. These components are crucial in detecting specific biomarkers that help determine a patient’s eligibility for precision treatments, particularly in oncology, cardiovascular diseases, and rare genetic disorders.
- Based on indication, oncology held the dominant market share in 2024, driven by the increasing global cancer burden and the growing demand for personalized medicine. CDx plays a crucial role in identifying biomarkers that help select targeted therapies, improving treatment outcomes for cancer patients.
- Based on technology, the Polymerase Chain Reaction (PCR) segment dominated the companion diagnostics market in 2024, holding a 27.7% share. Real-time PCR assays are widely used due to their high specificity and sensitivity, making them a preferred method for identifying cancer biomarkers
- Based on sample type, tissue samples held the largest market share of 62.7% in 2024, driven by the widespread adoption of biomarker-based tissue testing for targeted therapies. Tissue samples are essential for identifying genetic mutations and protein expressions in solid tumors, guiding precision medicine in oncology.
- Based on end use, the hospitals and physician laboratories segment dominated the oncology companion diagnostics market, holding a 38.6% share in 2024. Hospitals typically offer a comprehensive range of cancer diagnostic tests to address the increasing cancer burden and aging populations.
- North America dominated the global market with a market share of 40.2% in 2024. Primarily due to advanced healthcare infrastructure, substantial healthcare expenditure, and a robust regulatory framework that expedites approvals for new diagnostic technologies
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This Report Addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Companion Diagnostics Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Companion Diagnostics Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
3.4.3. Pipeline
3.4.4. Case Study
Chapter 4. Companion Diagnostics Market: Product and Services Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Companion Diagnostics Market: Product and Services Movement Analysis, 2024 & 2030 (USD Million)
4.3. Assays, Kits, and Reagents
4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Instruments and Systems
4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Software and Services
4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Companion Diagnostics Market: Indication Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Companion Diagnostics Market: Indication Movement Analysis, 2024 & 2030 (USD Million)
5.3. Oncology
5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Infectious Diseases
5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Cardiovascular Diseases
5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Neurological Disorders
5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other Indications
5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Companion Diagnostics Market: Technology Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Companion Diagnostics Market: Sample Type Movement Analysis, 2024 & 2030 (USD Million)
6.3. Polymerase Chain Reaction (PCR)
6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Next-generation Sequencing (NGS)
6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. In-situ Hybridisation (ISH)
6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.6. Immunohistochemistry (IHC)
6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.7. Magnetic Resonance Imaging (MRI)
6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.8. Other Technology
6.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Companion Diagnostics Market: Sample Type Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Companion Diagnostics Market: Sample Type Movement Analysis, 2024 & 2030 (USD Million)
7.3. Tissue Samples
7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Blood Samples
7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Other Sample Types
7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Companion Diagnostics Market: End Use Estimates & Trend Analysis
8.1. Segment Dashboard
8.2. Companion Diagnostics Market: End Use Movement Analysis, 2024 & 2030 (USD Million)
8.3. Academic and Research Centers
8.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.4. Hospitals and Physician Laboratories
8.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.5. CROs
8.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.6. Reference Laboratories
8.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.7. Pharmaceutical and Biotechnology Companies
8.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
8.8. Other End-use
8.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Companion Diagnostics Market: Regional Estimates & Trend Analysis
9.1. Companion Diagnostics Market Share, By Region, 2024 & 2030 (USD Million)
9.2. North America
9.2.1. North America Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.2. U.S.
9.2.2.1. U.S. Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.3. Canada
9.2.3.1. Canada Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.2.4. Mexico
9.2.4.1. Mexico Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3. Europe
9.3.1. Europe Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.2. UK
9.3.2.1. UK Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.3. Germany
9.3.3.1. Germany Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.4. France
9.3.4.1. France Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.5. Italy
9.3.5.1. Italy Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.6. Spain
9.3.6.1. Spain Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.7. Denmark
9.3.7.1. Denmark Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.8. Sweden
9.3.8.1. Sweden Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.3.9. Norway
9.3.9.1. Norway Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4. Asia Pacific
9.4.1. Asia Pacific Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.2. Japan
9.4.2.1. Japan Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.3. China
9.4.3.1. China Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.4. India
9.4.4.1. India Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.5. Australia
9.4.5.1. Australia Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.6. South Korea
9.4.6.1. South Korea Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.4.7. Thailand
9.4.7.1. Thailand Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5. Latin America
9.5.1. Latin America Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.2. Brazil
9.5.2.1. Brazil Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.5.3. Argentina
9.5.3.1. Argentina Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6. Middle East and Africa
9.6.1. Middle East and Africa Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.2. South Africa
9.6.2.1. South Africa Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.3. Saudi Arabia
9.6.3.1. South Africa Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.4. UAE
9.6.4.1. UAE Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
9.6.5. Kuwait
9.6.5.1. Kuwait Companion Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis by Key Market Participants
10.2. Company Categorization
10.3. Company Heat Map Analysis
10.4. Company Profiles
10.4.1. QIAGEN
10.4.1.1. Participant’s Overview
10.4.1.2. Financial Performance
10.4.1.3. Product and Services Benchmarking
10.4.1.4. Recent Developments/ Strategic Initiatives
10.4.2. Agilent Technologies, Inc.
10.4.2.1. Participant’s Overview
10.4.2.2. Financial Performance
10.4.2.3. Product and Services Benchmarking
10.4.2.4. Recent Developments/ Strategic Initiatives
10.4.3. Abbott
10.4.3.1. Participant’s Overview
10.4.3.2. Financial Performance
10.4.3.3. Product and Services Benchmarking
10.4.3.4. Recent Developments/ Strategic Initiatives
10.4.4. Thermo Fisher Scientific, Inc.
10.4.4.1. Participant’s Overview
10.4.4.2. Financial Performance
10.4.4.3. Product and Services Benchmarking
10.4.4.4. Recent Developments/ Strategic Initiatives
10.4.5. F. Hoffmann La Roche Ltd
10.4.5.1. Participant’s Overview
10.4.5.2. Financial Performance
10.4.5.3. Product and Services Benchmarking
10.4.5.4. Recent Developments/ Strategic Initiatives
10.4.6. Foundation Medicine
10.4.6.1. Participant’s Overview
10.4.6.2. Financial Performance
10.4.6.3. Product and Services Benchmarking
10.4.6.4. Recent Developments/ Strategic Initiatives
10.4.7. Myriad Genetics
10.4.7.1. Participant’s Overview
10.4.7.2. Financial Performance
10.4.7.3. Product and Services Benchmarking
10.4.7.4. Recent Developments/ Strategic Initiatives
10.4.8. Illumina, Inc.
10.4.8.1. Participant’s Overview
10.4.8.2. Financial Performance
10.4.8.3. Product and Services Benchmarking
10.4.8.4. Recent Developments/ Strategic Initiatives
List of Tables
Table 1 List of abbreviation
Table 2 Global companion diagnostics market, by region, 2018 - 2030 (USD Million)
Table 3 Global companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 4 Global companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 5 Global companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 6 Global companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 7 Global companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 8 North America companion diagnostics market, by country, 2018 - 2030 (USD Million)
Table 9 North America companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 10 North America companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 11 North America companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 12 North America companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 13 North America companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 14 U.S. companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 15 U.S. companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 16 U.S. companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 17 U.S. companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 18 U.S. companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 19 Canada companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 20 Canada companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 21 Canada companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 22 Canada companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 23 Canada companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 24 Mexico companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 25 Mexico companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 26 Mexico companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 27 Mexico companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 28 Mexico companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 29 Europe companion diagnostics market, by country, 2018 - 2030 (USD Million)
Table 30 Europe companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 31 Europe companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 32 Europe companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 33 Europe companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 34 Europe companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 35 UK companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 36 UK companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 37 UK companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 38 UK companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 39 UK companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 40 Germany companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 41 Germany companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 42 Germany companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 43 Germany companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 44 Germany companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 45 France companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 46 France companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 47 France companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 48 France companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 49 France companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 50 Italy companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 51 Italy companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 52 Italy companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 53 Italy companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 54 Italy companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 55 Spain companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 56 Spain companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 57 Spain companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 58 Spain companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 59 Spain companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 60 Denmark companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 61 Denmark companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 62 Denmark companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 63 Denmark companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 64 Denmark companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 65 Sweden companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 66 Sweden companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 67 Sweden companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 68 Sweden companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 69 Sweden companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 70 Norway companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 71 Norway companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 72 Norway companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 73 Norway companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 74 Norway companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 75 Asia Pacific companion diagnostics market, by country, 2018 - 2030 (USD Million)
Table 76 Asia Pacific companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 77 Asia Pacific companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 78 Asia Pacific companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 79 Asia Pacific companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 80 Asia Pacific companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 81 Japan companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 82 Japan companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 83 Japan companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 84 Japan companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 85 Japan companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 86 China companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 87 China companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 88 China companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 89 China companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 90 China companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 91 India companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 92 India companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 93 India companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 94 India companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 95 India companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 96 Australia companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 97 Australia companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 98 Australia companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 99 Australia companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 100 Australia companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 101 South Korea companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 102 South Korea companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 103 South Korea companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 104 South Korea companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 105 South Korea companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 106 Thailand companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 107 Thailand companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 108 Thailand companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 109 Thailand companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 110 Thailand companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 111 Latin America companion diagnostics market, by country, 2018 - 2030 (USD Million)
Table 112 Latin America companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 113 Latin America companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 114 Latin America companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 115 Latin America companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 116 Latin America companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 117 Brazil companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 118 Brazil companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 119 Brazil companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 120 Brazil companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 121 Brazil companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 122 Argentina companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 123 Argentina companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 124 Argentina companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 125 Argentina companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 126 Argentina companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 127 MEA companion diagnostics market, by country, 2018 - 2030 (USD Million)
Table 128 MEA companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 129 MEA companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 130 MEA companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 131 MEA companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 132 MEA companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 133 South Africa companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 134 South Africa companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 135 South Africa companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 136 South Africa companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 137 South Africa companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 138 Saudi Arabia companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 139 Saudi Arabia companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 140 Saudi Arabia companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 141 Saudi Arabia companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 142 Saudi Arabia companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 143 UAE companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 144 UAE companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 145 UAE companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 146 UAE companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 147 UAE companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 148 Kuwait companion diagnostics market, by product and services, 2018 - 2030 (USD Million)
Table 149 Kuwait companion diagnostics market, by indication, 2018 - 2030 (USD Million)
Table 150 Kuwait companion diagnostics market, by technology, 2018 - 2030 (USD Million)
Table 151 Kuwait companion diagnostics market, by sample type, 2018 - 2030 (USD Million)
Table 152 Kuwait companion diagnostics market, by end-use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Companion Diagnostics market segmentation
Fig. 2 Data analysis models
Fig. 3 Market formulation and validation
Fig. 4 Data validating & publishing
Fig. 5 Market research process
Fig. 6 Information procurement
Fig. 7 Primary research
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD modelling for market share assessment
Fig. 10 Market formulation & validation
Fig. 11 Commodity flow analysis
Fig. 12 Market outlook
Fig. 13 Segment snapshot - 1
Fig. 14 Segment snapshot - 2
Fig. 15 Competitive landscape snapshot
Fig. 16 Market trends & outlook
Fig. 17 Porter’s five force analysis
Fig. 18 PESTEL analysis
Fig. 19 Companion Diagnostics market: Product and Services outlook key takeaways
Fig. 20 Companion Diagnostics market: Product and Services movement analysis
Fig. 21 Assays, kits, and reagents market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Instruments and systems market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Software and services market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Companion Diagnostics market: Indication outlook key takeaways
Fig. 25 Companion Diagnostics market: Indication movement analysis
Fig. 26 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Infectious diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Cardiovascular diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Neurological disorders market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Other Indications market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Companion Diagnostics market: Technology outlook key takeaways
Fig. 32 Companion Diagnostics market: Technology movement analysis
Fig. 33 Polymerase Chain Reaction (PCR) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Next-generation Sequencing (NGS) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 In-situ Hybridisation (ISH) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Immunohistochemistry (IHC) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Magnetic Resonance Imaging (MRI) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Other technology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Companion Diagnostics market: Sample Type outlook key takeaways
Fig. 40 Companion Diagnostics market: Sample Type movement analysis
Fig. 41 Tissue samples market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 Blood samples market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 Other sample types market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Companion Diagnostics market: End-use outlook key takeaways
Fig. 45 Companion Diagnostics market: End-use movement analysis
Fig. 46 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Clinics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Diagnostics Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Academic and Research Centers
Fig. 50 Hospitals and Physician Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 CROs market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Reference Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 Pharmaceutical and Biotechnology Companies market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 Other End-use market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Regional marketplace outlook, 2024 & 2030 (USD Million)
Fig. 56 Regional marketplace: Key takeaways
Fig. 57 North America companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 Key country dynamics
Fig. 59 U.S. companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Key country dynamics
Fig. 61 Canada companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 62 Key country dynamics
Fig. 63 Mexico companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Europe companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 65 Key country dynamics
Fig. 66 UK companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 67 Key country dynamics
Fig. 68 Germany companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 69 Key country dynamics
Fig. 70 France companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 71 Key country dynamics
Fig. 72 Spain companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 73 Key country dynamics
Fig. 74 Italy companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 75 Key country dynamics
Fig. 76 Denmark companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 77 Key country dynamics
Fig. 78 Sweden companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 79 Key country dynamics
Fig. 80 Norway companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 81 Asia Pacific companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 82 Key country dynamics
Fig. 83 Japan companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 84 Key country dynamics
Fig. 85 China companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 86 Key country dynamics
Fig. 87 India companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 88 Key country dynamics
Fig. 89 Australia companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 90 Key country dynamics
Fig. 91 South Korea companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 92 Key country dynamics
Fig. 93 Thailand companion diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 94 Key country dynamics
Fig. 95 Market participant categorization
Fig. 96 Companion Diagnostics market position analysis, 2023
Fig. 97 Strategic framework
Companies Mentioned
- QIAGEN
- Agilent Technologies, Inc.
- Abbott
- Thermo Fisher Scientific, Inc.
- F. Hoffmann La Roche Ltd
- Foundation Medicine
- Myriad Genetics
- Illumina, Inc.
Methodology
LOADING...
